Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ACACB | O00763 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12204100 | 1.00 | SIGMAR1 (0.57) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL12204083 | 1.00 | SIGMAR1 (0.57) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL29729736 | 0.83 | NPC1 (0.58) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL30477284 | 0.83 | SIGMAR1 (0.55) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL12462450 | 0.81 | ALDH1A1 (0.71) | MEN1KMT2ANPC1RAB9ACYP1A2 | |
| SCHEMBL10912057 | 0.81 | MEN1 (0.67) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL12204092 | 0.81 | ACACB (0.55) | MEN1KMT2AACACB | |
| SCHEMBL15218455 | 0.81 | ALDH1A1 (0.71) | MEN1KMT2ANPC1RAB9ACYP1A2 | |
| SCHEMBL10912055 | 0.81 | MEN1 (0.67) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL5187405 | 0.81 | ACACB (0.55) | MEN1KMT2AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183232-B1 | MONOFLUOROALKYL DERIVATIVES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7135487-B2 | such as N-2-(4-Bromophenyl)propyl methanesulfonamide; sulfonamidation of the amine; glutamate receptor potentiators | ELI LILLY AND COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-7034045-B1 | Monofluoroalkyl derivatives | ELI LILLY AND COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | ARNOLD MACKLIN B | 2006-02-09 | — | — | US | disclosed |
| US-6911476-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1528055-A2 | Sulphonamide Derivatives | Eli Lilly & Company (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-0860428-B1 | Sulphonamide derivatives | LILLY CO ELI (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | KNOBELSDORF JAMES ALLEN (US) | 2004-03-18 | — | — | US | disclosed |
| US-20030225266-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-6596716-B2 | 2-propane-sulphonamide derivatives | ELI LILLY AND COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-6500865-B1 | POTENTIATING GLUTAMATE RECEPTORS BY ADMINISTERING N-1-(4-(4-(2-METHANESULFONAMIDO ETHYL)PHENY)PHENYL)ETHYL 2-PROPANE SULFONAMIDE FOR LEARNING ENHANCEMENT AND PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS, PSYCHOSIS OR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY | 2002-12-31 | — | — | US | disclosed |
| EP-1265857-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1183232-A2 | MONOFLUOROALKYL DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| US-20020002158-A1 | Sulphonamide derivatives | ARNOLD MACKLIN B (US) | 2002-01-03 | — | — | US | disclosed |
| US-6303816-B1 | Sulphonamide derivatives | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| WO-2001068592-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2000066546-A2 | MONOFLUOROALKYL DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000006537-A1 | N-SUBSTITUTED SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006083-A2 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | GRIN2C, GLRA2, GLRA1 | SIGMAR1 21/4885TAAR1 163/4885SLC18A2 165/4885 |
| US-20020002158-A1 | Sulphonamide derivatives | GRIN2C, GRM1, GRM3 | SIGMAR1 29/4885TAAR1 150/4885SLC18A2 338/4885 |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | GRIN2A, GRIN2B, GABRE | SIGMAR1 98/4885TAAR1 119/4885SLC18A2 46/4885 |
| US-20030225266-A1 | Sulfonamide derivatives | GRIN2A, GRM2, GRIA2 | SIGMAR1 173/4885TAAR1 189/4885SLC18A2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.